Buy Aranesp

Aranesp (darbepoetin alfa) is approved by the FDA for the treatment of anemia (a disease, which decreases the number of red blood cells) associated with chronic renal failure or caused by chemotherapy. Darbepoetin alfa differs from recombinant human erythropoietin (epoetin alfa) mainly by duration of action. Aranesp retains its blood levels approximately three times longer, with a much longer therapeutic window. This means that patients will need to use darbepoetin alfa much less often than epoetin alfa. If epoetin alfa is usually used three times a week, darbepoetin is used three times less often. This greatly increases the comfort of using the drug in patients, especially if the patient undergoes medical examinations during treatment. Athletes engaged in aerobic sports use darbepoetin to produce red blood cells. That is not a secret, that in sports where stamina is necessary, the practice of doping blood has been popular for many years. This procedure involves the allocation and storage of a certain amount of red blood cells from the athlete's body for their further infusion into the blood. When adding red blood cells to the body before the competition (when the body already regains lost blood volume), the athlete has an increased concentration of red blood cells in the body. Consequently, blood begins to carry oxygen more efficiently, and athletes experience a significant increase in endurance. Such a procedure can be quite dangerous, since the proper storage and use of blood is a rather complicated process.

Darbepoetin alfa is a drug that basically corresponds to chemical doping of blood, and when you apply it you can achieve the same results.

Aranesp is produced using gene technology in Chinese hamster ovary cells (CHO-K1). Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Darbepoetin alfa contains five N-linked carbohydrate chains, while endogenous hormone and recombinant human erythropoietins (rchEpo) have only three chains. The additional sugar residues, from the molecular point of view, do not differ from those present in endogenous hormone. Due to the high carbohydrate content, Aranesp has a longer T1 / 2, as compared with rchEpo, and therefore more in vivo activity. Despite these changes in the molecular structure, darbepoetin alfa retains a very narrow specificity for the erythropoietin receptor.

Erythropoietin is a growth factor that basically stimulates the formation of red blood cells.

Aranesp has been developed by Amgen. In 2001, the US Food and Drug Administration (FDA) approved the sale of the drug for the first time. Amgen is the world's largest biotechnology company, which in 1984 first put the recombinant erythropoietin (epoetin alfa) on the US market. The main effect of darbepoetin is the development of an effective erythropoietic protein with a much longer duration, compared with an earlier recombinant erythropoietin, usually administered three times a week. Darbepoetin is recommended once a week, which provides a more comfortable use of epoetin alfa in patients who do not receive too frequent injections. Darbepoetin alfa has not yet achieved market success equal to the success of epoetin alfa, but since its release it is considered the most popular drug ever produced by Amgen.